Padma P. Tadi Uppala Discussed Research Analyzing Natural Therapies to Combat COVID-19

Video

A presentation from the AACR Virtual Meeting: COVID-19 and Cancer detailed a literature review of natural therapeutics and remedies to combat the SARS CoV-2 virus.

CancerNetwork® spoke with Padma P. Tadi Uppala, professor and director of the Public Health Program at Andrews University, regarding her research from the AACR Virtual Meeting: COVID-19 and Cancer.

Uppala, along with her research partners, performed an exploratory analysis about evidence-based natural therapies and foods that naturally enhance the immune system with the goal of combatting the SARS CoV-2 virus.

“It’s a systematic literature review of evidence-based natural therapies to prevent and treat COVID-19,” explained Uppala. “It’s based on the fact that SARS CoV-2 dysregulates the innate immune system, so I wanted to look at literature to find if natural therapies can strengthen the innate immune system.”

The results, which relied heavily on data about the 1918 Spanish Flu as well as existing literature, found that foods such as blueberries, garlic, and probiotics were shown to improve natural killer activity, while Vitamin C, Vitamin D, Zinc, and selenium were integral in immunity.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content